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An evaluation of the role of polyamines in different models of kidney
hypertrophy in mice. The role of ornithine decarboxylase (ODC) and
polyamines in kidney hypertrophy is controversial. Since part of this
controversy could be related to differences in the model system used by the
different authors, we studied the changes in renal ODC and polyamines in
six different models of kidney hypertrophy in mice, including compensa-
tory renal hypertrophy produced by unilateral nephrectomy, experimental
diabetes, potassium depletion and treatment with hormones such as
testosterone, thyroxine and fluorocortisone. Only in the case of renal
hypertrophy produced by testosterone administration was there a signifi-
cant increase in ODC activity and putrescine content in the kidneys.
However, the concomitant treatment with difluoromethylornithine
(DFMO), an irreversible inhibitor of ODC, as a 2% solution in the
drinking water completely abolished the increase of renal ODC, but the
kidney weights increased and other androgenic effects, such as the
induction of renal /3-glucuronidase, were not affected. Moreover, DFMO-
treatment did not prevent the kidney enlargement produced in other types
of hypertrophy, even in the cases associated with hyperplasia. The present
results support the premise that, at least in mice, the increase in ODC
activity and polyamine biosynthesis is not required for kidney growth, and
also that in most cases renal enlargement is not accompanied by any
increase in the polyamine content.
In most mammals, there are numerous causes that provoke
renal hypertrophy, mainly in the proximal tubule cells [1]. Com-
pensatory hypertrophy produced by removal of one kidney is one
of the models most extensively studied thus far in rodents [2—5].
However, the mechanisms responsible for kidney growth in
different types of renal enlargement are not known with certainty,
although several changes in cyclic nucleotide [6, 7] or phospho-
lipid metabolism [8], as well as in the synthesis of rRNA [9] and
polyamines [3, 10, 11] have been observed.
The polyamines putrescine, spermidine and spermine are ubiq-
uitous polycations that play an important role in cell growth and
differentiation [12, 131. Ornithine decarboxylase (ODC), a key
regulatory enzyme in the pathway of polyamine biosynthesis,
increases its activity in many processes of tissue regeneration [14,
15]. The gene encoding ODC has been recently proposed as a
protooncogene [16, 17], and ODC has been considered as one of
the mediators that could initiate renal hypertrophy [11, 18]. The
use of difluoromethylornithine (DFMO), an irreversible inhibitor
of ODC activity [19], to investigate the role of ODC and poly-
amines in compensatory growth both in renal and non-renal
tissues has produced contradictory results [10, 18, 20—241. Mouse
kidney is one of the tissues in which ODC and polyamines have
been studied in detail [18, 21, 25—28]. The increase in renal ODC
and putrescine content observed after testosterone administration
to mice has been proposed to be at least partially responsible for
kidney hypertrophy [18], although this has not been a consistent
observation [21, 24].
In this work we compared, in different models of renal hyper-
trophy in mice, the implication of ODC and polyamines in the
process of renal growth, using DFMO to investigate whether the
changes in renal content of these organic cations could play any
role in the process of kidney hypertrophy. The data are discussed
in the context of previous observations about the significance of
polyamines in renal growth.
Methods
Materials
L-[1-'4C]ornithine (56 Ci/mol) was obtained from New England
Nuclear (Dreieich, Germany). All other reagents were purchased
from Sigma Chemical Co. (St. Louis, MO, USA). DFMO was a
gift from the Merrell Dow Research Institute (Strasbourg,
France).
Animals
CDt mice were used in this study. Adult animals (60- to 80-
days-old) had free access to standard chow and water and were
exposed to a 12:12 hour light-dark cycle, under controlled tem-
perature (22°C) and humidity (50%). For all the models of kidney
hypertrophy adult female mice were used, since control females
(as opposed to male) have low values of renal ODC and do no
present the renal hypertrophy produced by testosterone. In the
case of the renal hypertrophy produced by unilateral nephrectomy
the process was studied both in adult and in preweanling animals.
Preweanling mice from different dams were randomized and
housed in groups of ten pups (mixture of male and female) with
a lactating mother.
Treatments
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Different experimental models of kidney hypertrophy were
used. In the model of renal hypertrophy produced by androgens,
adult female mice were treated with testosterone propionate (100
mg/kg) by subcutaneous injection of the hormone in a solution of
olive oil. In the acute treatment, the mice were sacrificed 60 hours
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after the injection (this time being sufficient to produce a sus-
tained increase of renal ODC); for the chronic treatment five
separate injections were given 48 hours apart, and the mice were
killed 10 days after the first injection. Control animals received
vehicle alone. DFMO was administered as a 2% solution in the
drinking water in the chronic treatment and the average fluid
intake was about 4 ml per day. In acute treatments, DFMO
(dissolved in 0.9% NaC1) was given as a single intraperitoneal
injection at a dose of 2 g/kg, where control animals received
vehicle alone.
In the model of kidney hypertrophy produced by unilateral
nephrectomy, this operation was performed in both adult female
and preweanling mice under ether anesthesia. The right kidney
was removed, weighed and stored at —70°C until analysis. The
remaining kidney was removed four hours or seven days later, and
was processed as mentioned above. No significant differences in
ODC activity between kidney of sham operated mice and the
removed kidney were observed. In the experiments with prewean-
ling mice, the animals were nephrectomized at the age of 15 days
and killed seven days later. Male and female litters were used in
this experiment since at this age the sexual renal dimorphism
observed in adult animals had not taken place. Experimental
diabetes was produced by treating adult female mice with a single
injection of alloxan (100 mg/kg, intraperitoneally) and the animals
were killed 7 or 15 days later. Only mice with blood glucose
concentration higher than 3 mg/mI were included in the diabetic
group; blood glucose concentration in control animals was 1.07
0.18 mg/mI. In the diabetic groupreceiving DFMO, DFMO
treatment was initiated immediately after alloxan administration.
Fluorocortisone (20 mg/kg) was administered dissolved in olive oil
by subcutaneous injection twice a day. Thyroxine was given by
daily subcutaneous injection at a dose of 0.5 mg/kg, dissolved in
olive oil. Animals were killed 15 days after the first injection.
Potassium deficiency was produced by feeding the mice during 20
days with a diet similar to control diet but containing 120 mg/kg
potassium (UAR 212K). Control animals were fed with standard
chow (UAR A03) containing 7.5 g/kg potassium.
Analytical methods
Animals were killed by cervical dislocation under ether anes-
thesia. The kidneys were collected, rinsed and weighed. For
enzymatic determinations, one kidney was homogenized by Poly-
tron in buffer containing 25 mm Tris-HC1 pH 7.2, 2 mM dithio-
threitol, 0.1 mrt pyridoxal phosphate, 0.1 mi EDTA and 0.25 M
sucrose. 13-Glucuronidase activity was determined in the crude
extract, while ODC was assayed in the supernatant obtained after
centrifugation at 20,000 X g for 30 minutes. /3-Glucuronidase
activity was measured by the method of Fishman [29], using
p-nitrophenyl-/3-D-glucuronide as a substrate. ODC activity was
measured as described elsewhere [30] with some modifications.
Samples containing 0.01 ml of kidney extract were incubated for
one hour at 37°C in a total volume of 0.0625 ml containing 25 mM
Tris-HC1 pH 7.2, 2 mivi dithiothreitol, 0.1 mivi pyridoxal phosphate,
0.1 mM EDTA, 0.04 M sucrose and 0.4 mvi L-[1-14C] ornithine
(specific activity 4.75 Ci/mol). '4C02 was trapped in a disc of filter
paper wetted in hyamine hydroxide and it was counted by liquid
scintillation.
Polyamine analysis was performed as previously described [31].
The kidney was homogenized in 0.4 M perchloric acid, and the
supernatant obtained after centrifugation at 8,000 X g was used
Table 1. Effect of testosterone on kidney weight and renal ODC
activity
Renal weight
mg
Relative kidney
weight
ODC
activity
Male
Control 278 32 17.7 1.4 2.57 0.43
Testosterone, acute 271 37 17.7 1.5 9.21 1.12°
Testosterone, chronic 328 4Ø 19.7 1.6" 10.70 1.2F°
Female
Control 162 15 12.7 1.3 0.12 0.02
Testosterone, acute 178 16 14.4 0.9 6.64 1.64°
Testosterone, chronic 271 33° 18.1 1.1C 14.80 2.03c
Adult mice were treated with testosterone propionate (100 mg/kg, s.c.)
60 hours before killing (acute treatment) or for ten days in the chronic
treatment (5 injections 48 hr apart). Relative kidney weight is expressed as
the ratio between the weight of a pair of kidneys (mg) and the body weight
(g). ODC activity is given in mol C02/hr g. Results are the mean su
from 10 or more mice per group.
ap < 0.001 vs. control male
hP < 0.05 vs. control male
P < 0.001 vs. control female
for polyamine determination, following the dansylation method
described by Seyler [32]. Dansylated polyamines were separated
by HPLC, using a Lichrosorb 10-RP-18 column (4.6 X 250 mm)
and acetonitrile:water mixtures (running from 70:30 to 96:4 ratio
during 25 mm of analysis) as the mobile phase. 1,6-Hexanedi-
amine was used as an internal standard. Detection of the deriva-
tives was achieved using a fluorescence detector, with a 340 nm
excitation filter and a 435 nm emission filter.
Statistical analysis
The data were analyzed by one-way analysis of variance fol-
lowed by Student's t-test for differences between means.
Results
Renal hypertrophy produced by testosterone
Table 1 shows the renal weight, normalized renal weight
(expressed as percent of body wt), and renal ODC activity in male
and female mice control and in groups treated with testosterone
propionate. As reported by others, a sexual dimorphic pattern in
kidney size and ODC activity can be clearly seen in control mice.
In both sexes, testosterone produced a marked increase in renal
size and ODC activity, these changes being more marked in
females.
To determine the implication of ODC and polyamines in
testosterone-mediated hypertrophy, female mice were treated
chronically with testosterone and DFMO, administered simulta-
neously as a 2% solution in the drinking water. Figure 1 shows
that DFMO had no effect on renal hypertrophy promoted by
testosterone, although the inhibitor completely abolished the
increase in ODC activity. DFMO did not affect the rise of renal
/3-glucuronidase activity, another enzyme regulated by testoster-
one in the mouse kidney. Table 2 shows polyamine concentration
in the kidneys of mice under different experimental conditions.
Testosterone produced a remarkable increase in putrescine and a
modest rise in spermidine, while no effect on spermine concen-
tration was observed. DFMO inhibited the increase of renal
polyamines, especially putrescine.
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50 Fig. 1. Effect of DFMO on kidney size and ODC
and j3-glucuronidase activities in testosterone-
treated mice. Female mice were treated with40 testosterone propionate (100 mg/kg, s.c.) for 10
days. One group received DFMO (2% in the
drinking water) simultaneously to testosterone30 treatment. Results are expressed as means
ScM of 7 mice per group. Relative kidney
weight is expressed as the ratio between the20 weight of a pair of kidneys (mg) and body wt
(g). Enzyme activities are given as jLmol of
substrate transformed per hr and g of tissue.
1 0 Symbols are: (U) control; (LI) testosterone; ()
testosterone + DFMO. Statistical significance:
(a) P < 0.001, (b) P < 0.01 vs. control group;
0 (c) P < 0.001 vs. testosterone group.
Tahle 2. Effect of DFMO on renal polyamine levels in female mice
treated with testosterone
Renal polyamines nmol/g
Putrescine Spermidine Spermine SPD/SPN
Control (5) 42 3 471 42 630 40 0.74 0.08
Testosterone (5) 386 57" 750 46k' 670 67 1.11 0.10"
Test + DFMO (5) 76 16" 520 6C 739 31 0.70 0.08
Female mice received 5 s.c. injections of testosterone propionate (100
mg/kg) every 48 hours during 10 days. DFMO was administered as 2%
solution in the drinking water from the day before testosterone. Results
are the mean SD. Number of animals per group is given in parenthesis.
up < 0.05, hP < 0.01 vs. control group
'P < 0.05, dp < 0.01 vs. testosterone group
Renal hypertrophy produced by unilateral nephrectomy
The role of ODC and polyamines on compensatory renal
hypertrophy in female mice was studied under different experi-
mental conditions. We selected female mice because they have
smaller kidneys than male and very low levels of renal ODC
compared to male kidney, and hence, increases in both parame-
ters can be properly determined without influence of physiological
variations of testosterone. Table 3 shows the effect of DFMO,
administered chronically in the drinking water, on renal hypertro-
phy produced after seven days of unilateral nephrectomy. The
compensatory hypertrophy was similar both in absence and in
presence of DFMO during the post-nephrectomy period. No
changes in renal ODC activity or renal polyamines were evident.
Another experiment showed that four hours after kidney removal,
a small but significant increase in the weight of the remnant
kidney was observed, although no significant change in ODC
activity took place. DFMO administered intraperitoneally imme-
diately before nephrectomy produced a significant effect neither
in kidney hypertrophy nor in ODC activity (Table 4). It is possible
that the weight increase could be the result of increased fluid
rather than true growth. The effect of nephrectomy on kidney
hypertrophy was also studied in preweanling mice, since in this
period renal hypertrophy is associated with hyperplasia. As shown
in Table 5, in unilaterally nephrectomized 15-day-old mice killed
seven days after nephrectomy, a clear increase in renal weight was
observed, which was additive to the normal kidney growth during
this neonatal period. ODC activity in the kidneys of neonatal mice
was very low compared to adult male, and no significant change
was related to hypertrophic nephrectomy. The comparison of the
effect of a single injection of testosterone on kidney size between
unilaterally nephrectomized and control mice is presented in
Table 6. In nephrectomized mice, testosterone still produced a
further increase in the renal weight. In this group the increase in
the renal weight produced by the combination treatment was 84%
over control, which was higher than the one produced by nephrec-
tomy (66%) or testosterone alone (16%). However, the rise in
renal ODC produced by testosterone was similar in control and in
the remnant hypertrophic kidney. Chronic DFMO treatment
during the post-nephrectomy period abolished the increase in
renal ODC activity but was unable to diminish the large renal
weight increase produced by the combination of nephrectomy
plus testosterone.
Renal hypertrophy produced in experimental diabetes
Experimental diabetes was produced in adult female mice by
treatment with alloxan. Only mice with hyperglycemia were
Tovar et al: Polyamines and renal hypertrophy 733
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Table 3. Effect of DFMO on renal weight, ODC activity and polyamines after 7 days of unilateral nephrectomy in adult mice
Renal
weight
.Relative kidney
weight ODC activity
Renal polyamines nmol/g
Putrescine Spermidine Spermine
Control (N = 10) 182 31 12.3 1.1 0.25 0.21 85 30 340 14 631 27
Nephrectomized (N =
Nephrectomized + DF
5)
MO (N = 5)
256 41
246 33
17.9 1.la
16.9 1.4
0.33 0.19
0.10 0.05
84 21
72 21
365 15
338 43
653 56
703 39
Adult female mice were nephrectomized and the remnant kidney removed after 7 days of nephrectomy. DFMO was given as a 2% solution in the
drinking water immediately after nephrectomy. Renal weight is expressed in mg; relative kidney weight as the ratio between a pair of kidneys (mg) and
the body weight (g). ODC activity is given in ,amol C021hr g.
a P < 0.001 vs. control group
Table 4. Early effects of nephrectomy on renal weight and ODC
activity
Renal weight
mg
Relative renal
weight
ODC
activity
Control 160 16 10.9 0.52 0.16 0.06
Nephrectomy
Control + DFMO
195 13
161 19
13.1 0.85
11.1 1.45
0.10 0.03
0.10 0.03
Nephrectomy + DFMO 209 19 14.3 0.85a 0.04 o.or
Ten female mice were unilaterally nephrectomized under ether anes-
thesia. Removed kidney was compared with remnant kidney after 4 hours
nephrectomy. One group (N = 5) received DFMO (2 g/kg) by i.p. injection
30 mm before nephrectomy. Relative renal weight is expressed as the ratio
between kidney weight (mg) and body weight (g). ODC is given in ismol
C02/hr g.
ap < 0.001 vs. control group
Table 5. Effect of unilateral nephrectomy on renal weight and ODC
activity in preweanling mice
Renal weight Relative kidney ODC
mg weight activity
15-Day-old control (N = 7) 61 5 10.1 0.5 23 3
22-Day-old control (N = 7) 109 6 12.2 0.4 31 7
22-Day-old nephrectomized 156 ioa 16.7 0.6 26 8(N =7)
Fifteen-day-old mice from two different litters were randomly divided in
two groups. In one group mice were nephrectomized and killed 7 days
after nephrectomy. The second group served as control and were killed at
the age of 22 days. The relative renal weight is expressed as the ratio
between the weight of a pair of kidneys (mg) and the body weight (g).
ODC activity is expressed as nmol C02/hr g.
a P < 0.001 vs. 22-day-old control
included in the group of diabetic mice. Table 7 shows that
diabetes produced a significant increase in kidney weight with no
change in renal ODC activity. DFMO given from the beginning of
diabetes did not prevent kidney enlargement, although it pro-
duced a decrease in renal ODC activity. The extension of the
diabetic period to 15 days increased further renal hypertrophy
with no significant change in ODC activity (data not shown).
Renal hypertrophy produced by other causes
Renal hypertrophy was also produced by treatment of female
mice with different hormones such as thyroxine and fluorocorti-
sone. Table 8 shows that after 15 days of hormone treatment, the
kidneys underwent a marked increase in weight with no significant
alteration of ODC activity. Potassium deficiency produced by
feeding mice with a low potassium diet caused a large hypertrophy
of the kidneys of female mice (around 90% increase in the relative
Table 6. Effect of testosterone on control and nephrectomized mouse
kidney
Renal weight
mg
Relative kidney
weight
ODC
activity
Control (N = 10) 170 13 12.2 1.1 0.22 0.10
Nephrectomized (N = 6) 263 21 20.3 O.9 0.26 0.08
Testosterone (N = 6) 187 12 14.1 0.8 6.26 0.91a
Nephrectomized + 299 22k' 22.4 0.6k' 7.21 0.79
testosterone (N = 10)
Nephrectomized + 306 32C 22.5 0.7c 0.17 05d
testosterone + DFMO
(N =6)
Adult female mice were unilaterally nephrectomized and killed 15 days
later. Two groups of nephrectomized mice and a group of control animals
received an injection of testosterone propionate (100 mg/kg) 60 hours
before killing. DFMO (2% in the drinking water was given immediately
after nephrectomy. Relative kidney weight is expressed as mg/g. ODC
activity is given in .tmol C02/hr g. Results are the mean SD.
ap < 0.001 vs. control
bP < 0.05 vs. nephrectomized group
Not significant vs. nephrectomized + testosterone groupdP < 0.001 vs. nephrectomized + testosterone group
Table 7. Effect of experimental diabetes on kidney size and renal ODC
activity
Renal weight
mg
Relative renal
weight
ODC
activity
Control 188 12 12.7 1.00 0.12 0.03
Diabetic 234 17 14.8 0.35k' 0.14 0.04
Diabetic + DFMO 220 11a,b 14.4 037a,b 0.06 0.03
Diabetes was produced by treating female mice with a single injection of
alloxan (100 mg/kg, i.p.) and mice were killed 7 days later. DFMO was
applied, as a 2% solution in the drinking water, from the begining of
alloxan treatment. Relative renal weight is expressed as mg/g. ODC
activity is given in jrmol C02/hr g. Results are the mean SD of 5 animals
per group.
a P < 0.01 vs. control
hNot significant vs. diabetic group
kidney weight respect to control females) and a decrease in renal
ODC activity (Table 9). When testosterone was administered to
potassium-deprived mice, it produced a further increment in the
renal size (138% increase in the relative kidney weight respect to
controls) and a dramatic increase in ODC activity. DFMO did not
affect the renal enlargement produced by the combination of
potassium deficiency plus testosterone, although it completely
prevented the rise of renal ODC.
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Renal weight
mg
Relative kidney
weight
ODC
activity
Control 196 11 12.3 0.27 0.14 0.05
Thyroxine 268 17 16.2 1.17 0.14 0.04
Fluorocortisone 271 29 15.9 0.81 0.09 0.03
Discussion
There are numerous causes that produce an increase in kidney
mass. In some cases, the kidney growth is produced predomi-
nantly by a process of cell enlargement (renal hypertrophy) rather
than by cell proliferation (renal hyperplasia). Although in the
hypertrophic kidney many cellular and biochemical events have
been observed [1, 4], it is still unknown whether these changes are
triggered in response to intrarenal or extrarenal mediators.
Among the local factors, ODC and polyamines have been consid-
ered as mediators in the process of renal hypertrophy, since
unilateral nephrectomy resulted in an increase in ODC activity in
the remaining kidney in the rat [3]. Increased ODC activity in rat
kidney undergoing hypertrophy in experimental diabetes has also
been described, suggesting that polyamines may be involved in
diabetic renal hypertrophy [33]. In mice a marked sexual dimor-
phism exists in kidney size [34, 35]. Experiments showing that the
androgenic treatment of female mice produced both an increase
in kidney mass and in renal ODC activity, led to the suggestion
that testosterone response in the kidney is mediated by putrescine
[18]. However, several studies in which DFMO, a specific and
irreversible inhibitor of ODC, has been used to investigate the
implication of ODC and polyamines, have shown opposite and
contradictory results [21, 24].
Our present results on the participation of ODC and poly-
amines in kidney hypertrophy have been obtained in different
models of kidney growth in an attempt to clarif' whether the increase
in polyamine biosynthesis is a common event in the different types of
kidney hypertrophy in mice, and also if the activation of ODC is an
obligatory requirement for renal growth.
Our results show that testosterone produced a marked enlarge-
ment of kidney size, and a dramatic increase in renal ODC and
f3-glucuronidase activities. These results are in general in agree-
ment with those reported by other authors [26, 28, 36, 37]. The
effect of testosterone in mouse kidney was dependent on the sex
and the extent of the treatment, female being more affected than
male mice. Testosterone-induced renal hypertrophy was not in-
fluenced by DFMO despite the fact that this compound produced
an almost total inhibition of ODC induction and prevented the
rise of renal putrescine and spermidine elicited by testosterone in
the kidney. DFMO had also no effect on the elevation of renal
/3-glucuronidase, which suggests that the enhancement in ODC
and polyamines is neither a crucial determinant for mice kidney
hypertrophy nor for other metabolic responses in the hypertro-
phic kidney. These results are in accordance with previous reports
[10, 21, 24] and in contrast with others [18]. In addition, we
Control (N = 10) 30.5 4.2
K deficient (N =6) 25.8 1.2
K deficient + 27.3 2.9
testosterone
(N= 10)
K deficient + 25.3 1.8 387 44b 30.2 19b 0.05 0.01c
testosterone +
DFMO (N = 6)
Potassium deficiency was produced by feeding female mice with a diet
with low potassium content for 20 days. Testosterone propionate (100
mg/kg, s.c.) was administered 5 days before killing (2 injections 48 hr
apart). A group of potassium deficient mice received DFMO treatment
(2% in the drinking water) while fed with low potassium chow. Relative
kidney weight is expressed as the ratio between renal weight (mg) and
body weight (g). ODC activity is given in j.mol C02/hr g. Results are the
mean SD of six mice per group.
ap < 0.001 vs. control
b P < 0.00 1 vs. control and K deficient groups
'P < 0.001 vs. K deficient + testosterone group
recently showed that DFMO did not affect kidney growth in
pubertal mice and also that polyamines did not seem to be related
with the higher rate of growth of male than female kidney during
this period [38].
The results concerning the implication of polyamines in com-
pensatory renal growth in mice, a process in which both hyper-
plastic and hypertrophic growth take place [1], showed that both
in preweanling and in adult mice, the enlargement of the remnant
kidney was not accompanied by any significant increase of ODC
activity either shortly after nephrectomy or seven days later.
However, a significant increase in the relative kidney weight
(around 20%) was already evident four hours after the nephrec-
tomy, reaching 45% after seven days. In both cases, the treatment
with DFMO did not affect the compensatory renal growth. Renal
polyamine levels in the hypertrophic kidneys were similar whether
mice received DFMO or not. These results obtained in mice does
not agree with those previously reported in rats [3, 11]. We did not
find increased ODC activity either shortly after nephrectomy, in
spite of evident hypertrophy, or after seven days of nephrectomy.
In our study, polyamine concentrations in the remnant kidney
remained constant, in opposition to what was found in rats [3]. A
more recent study has shown that the increase in renal ODC
activity and polyamine content observed after unilateral nephrec-
tomy in rats is not necessary for the hypertrophy process to occur
[10].
In our experimental model in mice, diabetes was accompanied
by an increase in the absolute and relative kidney weight, the
extent of kidney hypertrophy being related to diabetes duration.
However, no significant change in renal ODC was observed and
also DFMO treatment did not affect diabetic kidney hypertrophy.
These results again argue against a critical role of ODC and
polyamine synthesis in the process of renal hypertrophy, in
contradiction to the postulated role of polyamines in diabetic
renal hypertrophy in rats [33, 39].
In all other models of renal hypertrophy produced either by
Table 8. Effect of treatments with thyroxine and fluorocortisone on
renal weight and ODC activity
Table 9. Effect of potassium deficiency on renal hypertrophy and renal
ODC activity
Body
weight
g
Female mice were treated for 15 days with thyroxine (0.5 mg/kg, s.c.) or
fluorocortisone (20 mg/kg, s.c.). Relative renal weight is expressed as the
ratio between the weight of kidneys (mg) and body weight (g). ODC
activity is given as smol C02/hr g. Results are the mean SD of 6 mice
per group.
ap < 0.001
Renal
weight
mg
177 30
285 14
374 51b
Relative
kidney
weight
11.5 0.8
22.1 1.8
27.4 20b
ODC
activity
0.10 0.02
0.05 0.02
9.80 210b
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hormone treatment (thyroxine and fluorocortisone) or by potas-
sium depletion, we did not find changes in renal ODC associated
with renal growth. Bearing in mind that renal hypertrophy pro-
duced by potassium depletion, in contrast to the other causes of
renal hypertrophy used in our experiments, is not associated with
an elevation in the rate of glomerular filtration [1], we can
conclude that in mice, independently from the cause that produce
the hypertrophy, the process of renal growth requires neither the
elevation of ODC activity nor the increase of renal polyamines.
Our results clearly show that the hypertrophic kidney, as a
result of a first hypertrophic agent, can respond to a second
hypertrophic stimuli with an additional renal weight gain, and
leads us to speculate that different mediators could be implicated
in the process of renal hypertrophy. The fact that testosterone
produced a kidney enlargement similar to that produced by other
renotrophic agents in mice, despite the disparate response in
ODC and putrescine, suggests that the early enhancement of
polyamine biosynthesis elicited by testosterone in the mouse
kidney might be related to functions other than the growth itself,
and remains to be established. The lack of effect of DEMO on
renal growth in mice treated with two hypertrophic agents, in
which the magnitude of renal growth and stimulation of ODC are
remarkably high, clearly shows that the increase in renal ODC
activity is not required for growth even in cases such as potassium
deficiency in which renal hypertrophy is associated with hyperpla-
sia [1]. The present results also corroborate recent findings in
which DFMO did not affect renal enlargement in antifolate-
induced hyperplastic mouse kidney [24].
The divergent results observed on the role of polyamines in
kidney hypertrophy between rat and mouse might be ascribed to
differences in the mechanism of response of ODC in both species.
In this regard, it is known that there are regional, temporal and
quantitative differences in the expression of ODC gene between
mouse and rat kidneys [401. In rats, the possible relationship
between polyamines and tissue hypertrophy seems to be vety
complex, because some studies have shown that blockade of ODC
by DFMO impaired liver regeneration [20, 22] or kidney hyper-
trophy [39], while in others a lack of involvement of ODC in
processes such as cardiac [41] or renal hypertrophy [10], and liver
regeneration [23] has been demonstrated.
In conclusion, our experiments demonstrate that the increase in
renal ODC activity and polyamine biosynthesis is neither critical
to the process of renal hypertrophy in mice, nor a consequence of
the hypertrophy itself.
Acknowledgments
This work has been partially supported by grants DGICYT PB91-0583
and F1S93-1012.
Reprint requests to Dr. Rafael Penafiel, Department of Biochemistty and
Molecular Biology, School of Medicine, University of Murcia, 30100 Murcia,
Spain.
References
1. FINE LG, NORMAN J: Cellular events in renal hypertrophy. Annu Rev
Physiol 51:19—32, 1989
2. JOHNSON HA, VERA ROMAN JM: Compensatory renal enlargement:
hypertrophy vs hyperplasia. Am J Pathol 49:1—13, 1966
3. AUSTIN HA, GOLDIN H, GAYDOS D, PREUSS HG: Polyamine metab-
olism in compensatory renal growth. Kidney mt 23:581—587, 1983
4. FINE LG: The biology of renal hypertrophy. Kidney mt 29:619—634,
1986
5. HOANG T, BERGERON MD: Androgen modulation of ornithine decar-
boxylase and compensatory renal growth. Growth 51:202—212
6. SCHLONDORFF D, WEBER H: Cyclic nucleotide metabolism in com-
pensatory renal hypertrophy and neonatal kidney growth. Proc NatI
Acad Sci USA 73:524—528, 1976
7. DICKER SE, GREENBAUM AL: Changes in renal cyclic nucleotide
contents as a possible trigger to the initiation of compensatory renal
hypertrophy in rats.] Physiol London 271:505—514, 1977
8. TOBACK FG, SMITH PD, LOWENSTEIN LM: Phospholipid metabolism
in the initiation of renal compensatory growth after acute reduction of
renal mass. J Clin Invest 54:91—97, 1974
9. OULLETrE AJ, MOONKA R, ZELENETZ AD, MALT RA: Regulation of
ribosome synthesis during compensatory renal hypertrophy in mice.
Am J Physiol 253:C506—C513, 1987
10. HUMI'HREYS MH, ETHEREDGE SB, LIN SY, RmSTEIN J, MARTON LI:
Renal ornithine decarboxylase activity, polyamines and compensatory
renal hypertrophy in the rat. Am ] Physiol 255:F270—F277, 1988
II. BRANDT JTD, PIERCE DA, FAUSTO N: Ornithine decarboxylase activ-
ity and polyamine synthesis during compensatory hypertrophy. Bio-
chim Biophys Acta 279:184—193, 1972
12. PEGG AE, MCCANN PP: Polyamine metabolism and function in
mammalian cells and protozoans, in IS! Atlas Science: Biochemistry,
edited by GRINWADE AH, Philadelphia, Institute for Scientific Infor-
mation mc, 1988, p 11
13. PEGG AE: Polyamine metabolism and its importance in neoplastic
growth and as a target for chemotherapy. Cancer Res 48:759—774,
1988
14. JANNE A, POso H, RAINA A: Polyamines in rapid growth and cancer.
Biochim Biophys4cta 573:241—293, 1978
15. Oic. T, BORELLINI F: The role of ornithine decarboxylase and
polyamine biosynthesis in cellular development and differentiation, in
Ornithine Decarboxylase: Biology, Enzymology and Molecular Genetics,
edited by HAYASHI 5, New York, Pergamon Press, 1989, p 7
16. AUVINEN M, PAASINEN, A, ANDERSSON LC, HOLTrA E: Ornithine
decarboxylase activity is critical for cell transformation. Nature 360:
355—358, 1992
17. MOSHIER JA, DOSESCU J, SKUNCA M, LUK GD: Transformation of
NTH/3T3 cells by ornithine decarboxylase overexpression. Cancer Res
53:2618—2622, 1993
18. GOLDSTONE A, KOENING H, Lu C: Testosterone-dependent sexual
dimorphism of the mouse kidney is mediated by polyamines. Biochim
Biophys Res Commun 104:165—172, 1982
19. METCALF BW, BEY P, DANZIN C, JUNG MJ, CASARA J, VEVERT JP:
Catalytic irreversible inhibition of mammalian ornithine decarboxyl-
ase (EC 4.1.1.17) by substrate and product analogues. JAm Chem Soc
100:2551—2553, 1978
20. Poso H, PEGG AE: Effect of alpha-difluoromethylornithine on poly-
amine and DNA synthesis in regenerating liver. Reversal of inhibition
of DNA synthesis by putrescine. Biochim BiophysActa 696:179—186,
1982
21. BERGER FG, PORTER CW: Putrescine does not mediate the andro-
genie response in mouse kidney. Biochim Biophys Res Commun
138:771—777, 1986
22. LUK GD: Essential role of polyamine metabolism in hepatic regener-
ation. Inhibition of deoxyribonucleic acid and protein synthesis and
tissue regeneration by difluoromethylornithine in the rat. Gastroenter-
ology 90:1261—1267 1986
23. BEYER HS, ELLEFSON M, STANLEY M, ZIEVE L: Inhibition of increases
of ornithine decarboxylase and putrescine has no effect on rat liver
regeneration. Am J Physiol 262:G677—G684 1992
24. MANTENFFEL CYMBOROWSKA M, CHMURZYNSKA W, GRZELAKOWSKA
SZTABERT B: Polyamines and testosterone-induced hypertrophic and
antifolate-induced hyperplastic mouse kidney. Differential effect of
a-difiuoromethylornithine. Biochim Biophys Acta 1182:133—141, 1993
25. GRAHN B, HENNINGSSON SSG, KAHLSON G, ROSENGREN E: Alter-
ations in the activities of ornithine and histidine decarhoxylase
provoked by testosterone in mice. Br] Pharmacol 48:113—120, 1973
26. HENNINGSSON S, PERSSON L, ROSENGREN E: Polyamines and nucleic
acids in the mouse kidney induced to growth by testosterone propi-
Onate. Acta Physiol Scand 102:385—393, 1978
27. CAMERON R, HENNINGSSON 5, PERSSON L, ROSENGREN E: Effects of
Tovar et at: Polyamines and renal hypertrophy 737
1 ,3-diaminopropane on testosterone induced hypertrophy and poiy-
amine synthesis in mouse kidney. Acta Physiol Scand 106:299—305
28. PAJUNEN AEI, Is0MAA VV, JANNE OA, BARDIN CW: Androgenic
regulation of ornithine decarboxylase activity in mouse kidney and its
relationship to changes in cytosol and nuclear androgen receptor
concentrations. J Biol Chem 257:8190—8189, 1982
29. FISHMAN WH: -Glucuronidase, in Methods of Enzymatic Analysis (vol
2), edited by BERGMEYER HU, New York, Verlag Chemie/Academic
Press, 1974, p 9
30. SEELY JE, PEGG AE: Ornithine decarboxylase (mouse kidney), in
Methods in Enzymology (vol 94), edited by TABOR H, T.aoR CW, New
York, Academic Press, 1983, p 158
31. LOPEZ-BALLESTER JA, PENAFIEL R, CREMADES A, VALCARCEL MM,
SOLANO F, LOZANO JA: Effects of treatments with a-difluorometh-
ylornithine and hyperthermia on the growth and polyamine metabo-
lism of Harding-Passey murine melanoma.AnticancerRes 11:691—696,
1991
32. SElLER N: Liquid chromatographic methods for assaying polyamines
using prechromatographic derivatization, in Methods in Enzymology
(vol 94), edited by TABOR H, TABOR CW, New York, Academic Press,
1983, p 10
33. PEDERSEN SB, FLYVBJERG A, GRONBAEK H, RICHELSEN B: Increased
ornithine decarboxylase activity in kidneys undergoing hypertrophy in
experimental diabetes. Mol Cell Endocrinol 86:67—72, 1992
34. KOENING H, GOLDSTONE A, BLUME G, Lu Y: Testosterone-mediated
sexual dimorphism of mitochondria and lysosomes in mouse kidney
proximal tubules. Science 209:1023—1026, 1980
35. BARDIN CW, CATFERALL iF: Testosterone: A major determinant of
extragenital sexual dimorphism. Science 211:1285—1294, 1981
36. SWANK RJ, PAIGEN K, DAVEY R, CHAPMAN V, LABARCA C, WATSON
G, GANscuow K, BRANDT EJ, NOVAK E: Genetic regulation of
mammalian glucuronidase. Rec Prog Horm Res 34:401—436, 1978
37. CATFERALL iF, JANNE OA: Androgen action in mouse kidney: struc-
ture and regulation of the 13-glucuronidase and ornithine decarboxyl-
ase genes. Modem Cell Biol 6:1—28, 1988
38. SANCHEZ-CAPELO A, PEI4AFIEL R, TOVAR A, GALINDO J, CREMADES
A: Postnatal development of ornithine decarboxylase and polyamines
in the mouse kidney: Influence of testosterone. Biol Neonate 66:119—
127
39. PEDERSEN SB, FLYVBJERG A, RICHELSEN B: Inhibition of renal
ornithine decarboxylase activity prevents kidney hypertrophy in exper-
imental diabetes. Am J Physiol 264: C453—C456, 1993
40. CROZAT A, PALVIMO JJ, JULKLJNEN M, JANNE OA: Comparison of
androgen regulation of ornithine decarboxylase and 5-adenosylmethi-
onine decarbokylase gene expression in rodent kidney and accessory
sex organs. Endocrinology 130:1131—1144, 1992
41. DANzIN C, MAMONT PS: Polyamine inhibition in vivo and in organ
growth and repair, in Inhibition of polyamine metabolism, edited by
MCCANN PP, PEGG AE, SJOERDSMA A, Orlando, Academic Press,
1987, p 141
